Lantern Pharma (LTRN) Expected to Announce Earnings on Monday

Lantern Pharma (NASDAQ:LTRN) will likely be posting its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Lantern Pharma to post earnings of ($0.59) per share for the quarter.

Lantern Pharma Price Performance

NASDAQ LTRN opened at $3.80 on Friday. Lantern Pharma has a 1 year low of $2.79 and a 1 year high of $11.99. The firm has a market cap of $40.98 million, a price-to-earnings ratio of -2.13 and a beta of 1.64. The company has a fifty day moving average price of $4.27 and a 200-day moving average price of $3.78.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.